This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the recent approval of Alhemo (concizumab) in patients 12 and older with hemophilia.
Ticker(s): NVO, PFEWho's the expert?
Institution: Tulane
- Assistant Professor of Clinical Medicine Section of Hematology & Medical Oncology at Tulane School of Medicine & Associate Director of federally funded hemophilia treatment center
- Site PI and PI on several clinical and pre-clinical trials; clinical focus on hemostasis and clotting and platelet disorders.
- Research has focused on the role of ROTEM, a global visco-elastic study, as a biomarker for multiple hematologic disorders.
Interview Goalto discuss the current treatment landscape and the potential of Novo Nordisk's Alhemo (concizumab), which was recently approved as a once daily treatment for hemophilia a and b.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
